[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pelvic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pelvic-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,46,85,130,151,178,206,236,266,289,303,331,357,385,413,438,470,495,522,546,566,585],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053653","phase-3-evaluation-of-the-analgesic-effect-of-intramyometrial-botulinum-toxin-injection-via-hysteroscopy-in-pelvic-pain-suggestive-of-dysmenorrhea-100053653",false,"NCT06995287","Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea","Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea: A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study.","HYSTEROXINE","Inclusion Criteria:\n\n* Adult women who are not menopausal,\n* Presenting with:\n* Either severe primary dysmenorrhea, defined by an average pain intensity (VAS) ≥ 6\u002F10 over the last 3 months at the inclusion visit,\n* Or, in cases of amenorrhea under hormonal treatment, severe chronic pelvic pain (average VAS ≥ 6\u002F10 over the last 3 months), described as cramp-like, localized in the pelvic region, and similar to the initial dysmenorrhea pain.\n* Having failed optimal first-line medical treatment combining hormonal therapy and appropriate analgesics (Level I and II analgesics, and NSAIDs),\n* Having undergone a pelvic MRI within 1 year prior to the randomization visit that shows no evidence of deep infiltrating endometriosis or endometrioma, following systematic review by radiologists from the expert center managing the patient (if the pelvic MRI is deemed of insufficient quality for interpretation, a new MRI will be performed at the center),\n* Using a highly effective method of contraception (failure rate \\\u003C1%) for the entire duration of the follow-up period. Highly effective contraception methods are defined as one of the following: combined hormonal contraception (containing estrogen and progestin) with ovulation inhibition (oral, vaginal, or transdermal), progestin-only hormonal contraception with ovulation inhibition (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormonal system (IUS), condoms, bilateral tubal occlusion, vasectomized partner, or sexual abstinence,\n* Having a negative urine pregnancy test on the day of the procedure,\n* Having signed the informed consent form for the study at the M-1 visit.\n\nExclusion Criteria:\n\n* Pregnant or planning a pregnancy during the entire study period,\n* Currently breastfeeding,\n* Refusal to use effective contraception during the study and for 6 months after its completion,\n* Contraindications to botulinum toxin, including:\n* Generalized disorders of muscular activity (e.g., myasthenia gravis, Lambert-Eaton syndrome),\n* Ongoing treatment with aminoglycosides, peripheral muscle relaxants, or amino-4-quinolines,\n* Hypersensitivity to the active substance, human albumin, or sucrose,\n* Bleeding disorders or current treatment with anticoagulants,\n* Ongoing vaginal or upper genital tract infection,\n* Participation in another interventional clinical trial,\n* Inability to cooperate or understand the study requirements in a way that would allow strict adherence to the protocol,\n* Subject to legal protection measures (e.g., guardianship, curatorship, or judicial protection),\n* Not affiliated with the French social security system,\n* Unable to access the internet to complete questionnaires at Month 1 and Month 6.","FEMALE","18 Years",{"count":20,"type":21},222,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The objective of the study is to evaluate the global impression of improvement at 3 months following intramyometrial botulinum toxin injections via hysteroscopy in women with severe primary dysmenorrhea who have failed first-line medical treatment, compared to intramyometrial placebo injections.",[27,28],"Primary Dysmenorrhea","Chronic Pelvic Pain",[30,31,32],"Primary dysmenorrhea","injection","Botulimum toxin, Type A","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-02-09",{"date":41,"type":21},"2028-09-09",{"name":43,"class":44},"Nantes University Hospital","OTHER",8,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100644230","phase-4-cyclobenzaprine-for-postoperative-pain-in-minimally-invasive-hysterectomy-100644230","NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates",{"count":54,"type":21},36,[56],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[59,60,61,62,28,63,64,65,66],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[68,69,70,71,72,73],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":77,"type":37},"2026-06-24",{"date":79,"type":21},"2026-07-01",{"date":81,"type":21},"2026-12-01",{"name":83,"class":44},"Christiana Care Health Services",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":84},"100641011","measuring-pelvic-floor-muscle-fitness-before-and-after-treatment-100641011","NCT07605598","Measuring Pelvic Floor Muscle Fitness Before and After Treatment","Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain Before and After Myofascially-Directed Therapies","Inclusion Criteria:\n\nWomen over 18 years of age\n\nPelvic Pain for more than 3 months\n\nReport an average daily pain intensity score of at least 4 on a 0 to 10 scale\n\nPalpable trigger\u002Ftender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam\n\nWilling to refrain from new clinical treatment that may affect pain during the study period\n\nExclusion Criteria\n\nInability to participate in clinic visits\n\nPrior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®) in the past 6 months\n\nActive UTI or vaginal infection\n\nPregnancy or childbirth in the past 12 months, currently planning a pregnancy\n\nIllicit Drug addiction\u002Fregular use of controlled substances (including marijuana use in the past 2 weeks or during the study period)\n\nPelvic floor physical therapy in the past 3 months\n\nMalignancy or other serious medical condition (e.g., poorly controlled diabetes \\[HgA1c \\> 8\\], chronic renal disease \\[GFR \\\u003C30\\], neurologic or rheumatic disease)\n\nDiagnosed with an alternate cause of pelvic pain (e.g., ulcerative interstitial cystitis, vestibulodynia, vulvar dermatoses, dysmenorrhea)\n\nUrinary retention with a PVR \\>150 mL\n\nGreater than stage 3 pelvic organ prolapse\n\nIndwelling vaginal devices (e.g., pessary, contraceptive ring. Not including Mirena IUD) that cannot be removed for the study\n\nInability to sign an informed consent, fill out questionnaires, or complete study interviews",{"count":93,"type":21},120,[95],"NA","This study is being done to better understand and improve treatment for myofascial pelvic pain, a common cause of long-lasting pelvic pain in women. Myofascial pelvic pain is related to tight or dysfunctional pelvic floor muscles and can cause pain as well as bladder, bowel, and sexual problems. Current clinical evaluations mostly rely on physical examination and patient-reported symptoms and do not fully measure how the pelvic floor muscles are functioning.\n\nThe purpose of this study is to measure pelvic floor muscle function using a noninvasive imaging method called near-infrared spectroscopy, or NIRS. This method measures changes in muscle blood flow and oxygen levels during muscle contraction and relaxation. The study will examine whether pelvic floor muscle function improves after different treatments and whether these physiologic changes are associated with improvements in pain and symptoms.\n\nThe study will enroll 120 adult women who have had pelvic pain for at least three months and have pelvic floor muscle tenderness on examination. Participants will be randomly assigned to one of three groups: education with relaxation exercises, pelvic floor physical therapy focused on myofascial release, or vaginal medication used to help relax pelvic floor muscles.\n\nParticipants will take part in four study visits over a six-month period. During these visits, they will complete questionnaires about pain and pelvic symptoms, undergo pelvic floor examinations, and have pelvic floor muscle imaging using the NIRS device while performing brief muscle contractions and relaxations. Some visits will also include collection of blood, urine, and vaginal samples to measure inflammation.\n\nThe information gained from this study may help improve the diagnosis and treatment of myofascial pelvic pain by providing objective measures of pelvic floor muscle function and identifying which treatments are most effective for different patients.",[98,99,100,28],"Myofacial Pain","Pelvic Pain","Myofascial Pelvic Pain",[102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120],"myofascial pelvic pain","chronic pelvic pain","pelvic floor muscle dysfunction","pelvic floor myalgia","pelvic floor hypertonicity","Near-infrared spectroscopy","NIRS imaging","Pelvic floor muscle oxygenation","Pelvic floor muscle blood flow","Pelvic floor muscle fitness","Pelvic floor physical therapy","Myofascial release therapy","Pelvic floor relaxation therapy","Intravaginal diazepam","Intravaginal baclofen","Pelvic floor muscle relaxation medication","Women's pelvic pain","Noninvasive pelvic floor assessment","Pelvic floor imaging","2026-05-21",{"date":123,"type":37},"2026-05-26",{"date":125,"type":21},"2026-09-01",{"date":127,"type":21},"2029-07-01",{"name":129,"class":44},"University of California, Los Angeles",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":84},"100636680","impact-of-pelvic-pain-podcast-100636680","NCT07568834","Impact of Pelvic Pain Podcast","\"Impact of an Educational Podcast for Patients With Chronic Pelvic Pain\"","Inclusion Criteria:\n\n* Being seen as a new patient or consult visit by provider in the division of minimally invasive gynecology surgery for chronic pelvic pain or endometriosis\n* 18 years of age or older\n* Understand English\n* Has an email address and personal device with capability to listen to an audio podcast\n\nExclusion Criteria:\n\n* Not able to speak English\n* Being seen for acute pelvic pain",{"count":138,"type":21},100,[95],"The purpose of this research study is to study the impact of an educational podcast on pelvic pain. If you decide to take part in this research, you may receive the standard treatment for pelvic pain, or you may receive the standard treatment plus access to an educational podcast series. You will be randomly assigned to receive access to the podcast or to receive standard care. If you are assigned to receive access to the podcast, participating in this research will involve listening to a podcast series. All participants will complete three ten-minute online surveys over the course of 6 months. Reasons you may choose to participate in this research are if you want to learn more about pelvic pain and possible benefits of listening to the podcast, such as improved quality of life, reduced stigma, or increased satisfaction with your medical care.",[28,63],"2026-05-15",{"date":144,"type":37},"2026-05-19",{"date":146,"type":37},"2026-05-05",{"date":148,"type":21},"2027-08-01",{"name":150,"class":44},"Vanderbilt University Medical Center",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":177},"100584176","augmenting-urinary-reflex-activity-study-4-including-extended-indications-100584176","NCT06885931","Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)","Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System","AURA-4X","Inclusion Criteria:\n\n* Female. NB: the definition of female refers to sex at birth.\n* Adult: aged ≥ 22 years (at the time of informed consent signature).\n* Patient self-reports both stress and urge episodes (clinician-opinion on history taking).\n* Patient has failed to respond to or could not tolerate conservative treatment as determined by the treating health care provider.\n* Duration of urinary incontinence symptom ≥ 6 months prior to the screening baseline visit date.\n* Able and willing to voluntarily sign informed consent form.\n* Able to participate in all testing and follow-up clinic visits associated with study protocol.\n* Patient is mobile and able to use a toilet.\n* In the opinion of the Investigator, the patient is capable of independently using the system components (after training).\n\nExclusion Criteria:\n\n* Patient is pregnant, breastfeeding, or plans to become pregnant at any time in the future.\n* Patient is unwilling or unable to use contraception during sexual intercourse for the duration of the study.\n* In the event that patient becomes pregnant during or after the study, they are not prepared to inactivate device for the whole period of the pregnancy.\n* Any significant medical condition that, in the opinion of the Investigator, is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints.\n* History of major psychiatric or personality disorder.\n* Any neurological condition that in the opinion of the investigator may interfere with normal bladder function (e.g., stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or complete spinal cord injury).\n* Uncontrolled type I or type II diabetes (as defined by their routine care clinician or HBA1C ≥ 7.0).\n* History of cancer within 5 years prior to enrolment, except for a cancer that was determined to be free of systemic cancer risk, such as basal cell carcinoma.\n* Patient is taking antiplatelet and\u002For anticoagulant drugs including warfarin or newer alternatives (e.g., rivaroxaban, apixaban, dabigatran, edoxaban) which cannot be paused prior to surgery, or has a bleeding disorder that cannot be corrected prior to surgery.\n* Any clinical reason that, in the opinion of the Investigator, may compromise patient's safety during the study.\n* Currently participating in another interventional study. This excepts purely observational studies, e.g., registries.\n* Patient participation in vigorous physical activities where these cannot be restricted for a period of 6 weeks post-implantation.\n* Patient unwilling to stop any future participation in scuba diving below 10m. BMI ≥ 40kg\u002Fm2 or waist circumference \\> 127cm\n* Documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone.\n* Skin, orthopedic or neurological anatomical limitations at the site of implant that could prevent successful placement of an electrode or IPG. This includes active perineal sepsis or perianal sepsis (e.g., anal fistula and pilonidal sinus).\n* Knowledge of planned MRIs, diathermy, medical microwave exposure, high output ultrasonic exposure, or medical RF energy exposure.\n* Implantable neurostimulator or antennae, pacemaker or defibrillator in-situ (anywhere in body).\n\nExclusion Criteria (Urological):\n\n* Known diagnosis of interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines. Diagnosis of any other chronic pelvic or regional pain syndrome\n* Documented bladder emptying syndrome including neurogenic bladder.\n* Known abnormal post void residual (\\> 100 ml).\n* Any prolapse (symptomatic or asymptomatic) currently at or below the hymenal level Known urinary tract mechanical obstruction such as urethral stricture and\u002For bladder neck contracture.\n* Current symptomatic urinary tract infection (UTI) or more than 3 culture-proven UTIs in past year.\n* Current diagnosis of vesicoureteral reflux\n* Current diagnosis of bladder stones\n* History of bladder tumour (benign or malignant) -Suspected or proven pudendal nerve entrapment syndrome. In patients with co- existent chronic pelvic pain and urinary incontinence symptoms, Nantes criteria will be used for screening. Patients meeting essential criteria will be excluded from the study.\n* Suspected or proven severe pudendal nerve damage at discretion of clinician with or without specialist investigations\n* Any previous experience of pudendal nerve stimulation using an implanted lead.\n* Previous failure of SNM therapy (based on implantation; failed test phase is not an exclusion)\n* Major previous urethral or bladder surgery (excisional or reconstructive) at discretion of investigator\n* SUI surgery e.g. urethral slings, tapes, and bulking agents colposuspension within last 2 years; \\> 2 years at discretion of investigator\n* Prolapse surgery e.g. colposuspension \u002F colporrhaphy within last 12 months with current confirmation via pelvic exam of no recurrence \\> or = to Stage 2 pelvic organ prolapse\n* Previous use of bladder botox injections within last 6 months","22 Years",{"count":161,"type":21},86,[95],"Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.",[165,166,28,167],"Mixed Urinary Incontinence","Stress Urinary Incontinence (SUI)","Urge Urinary Incontinence","2026-05-13",{"date":142,"type":37},{"date":171,"type":37},"2025-06-24",{"date":173,"type":21},"2030-01",{"name":175,"class":176},"Amber Therapeutics Ltd","INDUSTRY",7,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":185,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":84},"100532108","brief-pain-exposure-therapy-bpet-for-nociplastic-pain-100532108","NCT06208514","Brief Pain Exposure Therapy (BPET) For Nociplastic Pain","BPET","Inclusion Criteria:\n\n* Able to read, write and speak English\n* Internet access and audio-visual conferencing capability (e.g., Zoom meetings by phone or computer) in the home\n\nFibromyalgia participants must have:\n\n* Physician diagnosis of fibromyalgia\n* OR: meet 2016 American College of Rheumatology (ACR) Criteria for FM: Widespread pain index score is ≥ 7 and symptom severity scale score is ≥ 5, or widespread pain index score is 4 to 6 and symptom severity score is ≥ 9\n* OR: have pain self-reported in 4 out of 7 body regions in the General Sensory Sensitivity (GSS)-brief body map AND Opioid Use Disorder diagnosis by a physician.\n\nLupus participants must have:\n\n* Physician diagnosis of systemic lupus erythematosus\n* AND: Have pain self-reported in 4 out of 7 body regions in the GSS-brief body map\n* AND: No change in medications or steroid dose for one month prior to entry (to avoid oscillation of steroid dosing during the study due to active disease).\n\nChronic Low Back Pain participants must have:\n\n* Low Back Pain for at least half the days over the past 6 months\n* Over the past 7 days, an average pain intensity of at least 4 out of 10\n\nExclusion Criteria:\n\n* Indication of a co-occurring (non-fibromyalgia OR non-lupus) cause of chronic pain (e.g., inflammatory arthritis, other autoimmune disorders, spinal cord injury, cancer)\n* Currently receiving cognitive-behavioral therapy or other psychological therapies for pain\n* Open litigation regarding chronic pain in the past 1 year, as assessed in preliminary study screening.\n* Inability to provide informed consent and complete study procedures (e.g., indications of suspected major cognitive impairment via observations of study staff during consenting) that would preclude comprehension or participation in study protocols.\n* Pregnant or breastfeeding\n* Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.\n* Lupus group only: taking \\>10 mg prednisone (or equivalent steroid) dose per day as an indicator of ongoing disease activity (with no other strict exclusions based on medications)\n* Chronic Pelvic Pain group only: surgery for any chronic pelvic pain related condition in the past 6 months\n* Chronic low back pain only: scheduled back surgery; leg pain that is greater than your back pain","ALL",{"count":187,"type":21},125,[95],"This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia (FM), Lupus, chronic pelvic pain, and chronic low back pain learn effective strategies for reducing pain, disability and other problems that can come with fibromyalgia, Lupus, chronic pelvic pain, and chronic low back pain (such as depression or anxiety).",[191,192,28,193],"Fibromyalgia","Lupus Erythematosus, Systemic","Chronic Low Back Pain (CLBP)",[195,196],"Pain exposure therapy","Telehealth-based behavioral intervention","2026-05-06",{"date":199,"type":37},"2026-05-11",{"date":201,"type":37},"2024-03-04",{"date":203,"type":21},"2027-07",{"name":205,"class":44},"University of Michigan",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":185,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":216,"studyType":217,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":84},"100630991","effects-of-microbiological-and-immunological-factors-on-the-lower-urinary-tract-100630991","NCT07494864","Effects of Microbiological and Immunological Factors on the Lower Urinary Tract","MiLUT","General inclusion criteria:\n\n* Women and men aged ≥ 18 years old\n* Able to give informed consent for participation in the study\n* Willing to adhere to the study protocol for the whole trial period\n* Willing to undergo repetitive in-and-out single catheterization Specific inclusion criteria for the different study arms Arm I: Healthy controls Arm II: Asymptomatic bacteriuria in subjects not requiring assisted bladder emptying Arm III: Asymptomatic bacteriuria in subjects relying on some type of catheter for bladder emptying Arm IV: Acute non-catheter associated UTIs Arm V: Recurrent non-catheter associated UTIs Arm VI: Acute catheter-associated UTI Arm VII: Recurrent catheter-associated UTI Arm VIII: Chronic pelvic pain Arm IX: Non-neurogenic overactive bladder syndrome Arm X: Non-muscle-invasive bladder cancer\n\nExclusion Criteria:\n\n* Current antibiotic treatment or antibiotic treatment within the last 21 days (except for study arms IV-VII)\n* UTI secondary to diagnosed treatable pathologies (i.e., bladder stones, enterovesical fistula etc.) and requiring specific therapy Current therapies for preventing UTIs (e.g., urine acidification, phytotherapy) or such therapies within the last 21 days (except for study arms IV-VII)\n* Deterioration of the upper urinary tract requiring medical intervention\n* Immunomodulatory therapies (apart from routine vaccination)\n* Congenital or acquired malformations of the LUT (study arm I only)\n* Immunosuppressant therapy (study arm I only)\n* Need for antiviral medication (study arm I only)\n* Significant pre-existing or current severe systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including anamnestic known AIDS) or kidney disease; or active malignancy (except from bladder cancer) or any other condition as determined by history or laboratory investigation that could cause susceptibility to infections.\n* Presence of any unstable medical or psychiatric condition (defined by the Diagnostic and Statistical Manual of Mental Disorders, Edition 4 (DSM-IV)) that could reasonably have been expected to subject the patient to unwarranted risk from participation in the study or result in a significant deterioration of the patient's clinical course.\n* Drug\u002Falcohol dependence (as defined by DSM-IV) any time during the 6 months preceding study entry.\n* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (\\> 5 mIU\u002FmL).\n* Suspected inability to follow the procedures of the trial (e.g., language problems, psychological disorders, dementia) such that the validity of the patient's data could be compromised.\n* Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.\n* Patients who are unconscious, including those patients who are unconscious due to medication causing marked sedation.\n* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure.",true,{"count":215,"type":21},800,"1 Year","OBSERVATIONAL","Millions of patients of all ages suffer worldwide from diverse urinary pathologies, such as lower urinary tract (LUT) dysfunction, bladder pain syndrome, urinary tract infections (UTIs), or bladder cancer. The research project investigates the interplay between the bladder and the microbiome. The goal is to evaluate the association of microbiological and immunological factors with lower urinary tract health in humans.",[220,221,222,223,224,28,225,226],"Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying","Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter","Recurrent Non-catheter Associated UTIs","Acute Catheter-associated UTI (CAUTI)","Recurrent Catheter-associated UTI (CAUTI)","Non-neurogenic Overactive Bladder Syndrome \u002F LUT Symptoms","Non-muscle-invasive Bladder Cancer","2026-03-20",{"date":229,"type":37},"2026-03-27",{"date":231,"type":37},"2023-06-01",{"date":233,"type":21},"2026-11-30",{"name":235,"class":44},"University of Zurich",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":185,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":217,"phases":4,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100630388","knowledge-coping-strategies-and-sexual-function-in-chronic-pelvic-pain-100630388","NCT07487025","Knowledge, Coping Strategies, and Sexual Function in Chronic Pelvic Pain","Association Between Knowledge About Pain, Coping Strategies, and Sexual Function in Adults With Chronic Pelvic Pain: A Cross-Sectional Observational Study","KCS-CPP","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Clinical diagnosis of chronic pelvic pain lasting at least 6 months.\n* Ability to understand spoken and written Spanish.\n* Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Current pregnancy.\n* Major pelvic surgery within the previous 3 months.\n* Active pelvic infection or active neoplastic disease.\n* Cognitive impairment or any condition preventing completion of questionnaires.\n* Inability to understand Spanish.",{"count":245,"type":21},50,"This study aims to explore the relationships between knowledge about pain, coping strategies, and sexual function in adults with chronic pelvic pain. Chronic pelvic pain is a persistent condition that can affect physical health, emotional wellbeing, and daily life. Research suggests that understanding of pain and coping responses may influence how people experience chronic pain and its impact on quality of life.\n\nParticipants will be adults diagnosed with chronic pelvic pain who attend hospital outpatient clinics. Those who agree to participate will complete a set of questionnaires assessing knowledge about pain, coping strategies, sexual function, and basic demographic and pain-related information. Participation is voluntary and anonymous and involves a single assessment session lasting approximately 10-15 minutes. No treatments or interventions are provided as part of this study.\n\nThe results will contribute to understanding how knowledge about pain, coping strategies, and sexual function interact in people with chronic pelvic pain and may inform future educational and clinical approaches.",[28,248],"Chronic Pain",[250,251,252,253,254,255,256,257],"Chronic pelvic pain","pain knowledge","pain education","coping strategies","pain catastrophizing","sexual function","cross-sectional study","observational study",{"date":259,"type":37},"2026-03-25",{"date":261,"type":21},"2026-03",{"date":263,"type":21},"2026-04",{"name":265,"class":44},"Maria Blanco Diaz",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":84},"100575883","national-program-to-overcome-pelvic-pain-study-poppy-100575883","NCT06778070","National Program to Overcome Pelvic Pain studY (POPPY)","POPPY","Inclusion Criteria:\n\n* Women (individuals reporting female sex assigned at birth who self-identify as women or non-binary) aged 18 years or older\n* Report chronic or recurrent pain in the pelvis (between or below the anterior iliac crests) for at least 6 months\n* Report at least moderate pain intensity based on a screening pain log\n* Report prior clinical evaluation of their pelvic pain by a healthcare professional including at least a superficial pelvic exam\n* Willing to refrain from initiating new clinical treatments that may affect their pain during the study period\n\nExclusion Criteria:\n\n* Report pelvic pain occurring exclusively with menses or exclusively during sexual intercourse (although candidates with at least some pain between menses or intercourse are still eligible)\n* Participation in organized yoga classes or muscle strengthening programs (e.g., Pilates) in the past 4 weeks, or any prior yoga therapy specifically directed at pelvic pain\n* Lacking technical requirements to complete intervention classes by video, including no access to broadband internet or a Zoom-compatible device larger than a smartphone \\[display screen at least 7 inches in diagonal\\] (although the study team may loan devices to participants from underrepresented backgrounds)\n* Currently pregnant (by self-report or screening test), pregnant within the past 12 weeks, or planning pregnancy during the study period\n* Diagnosed with an alternate, reversible cause of pelvic pain that is unlikely to respond to yoga and requires another treatment modality (e.g., current pelvic infection or a gynecologic dermatosis)\n* Surgery or irradiation to the genital or pelvic structures within the past 12 weeks, or anticipating upcoming surgery or irradiation to these structures during the study period\n* Initiation, dose escalation, or weaning of pharmacologic agents that may affect pelvic pain severity in the past 4 weeks, such as analgesics, antidepressants, or anticonvulsants-(however, women on stable doses of these medications for at least 4 weeks will still be eligible)\n* Use of formal psychological therapies specifically for pelvic pain (e.g., systematic desensitization, cognitive therapy, relaxation therapy) within 4 weeks of screening, or plans to engage in these therapies during the study period\n* Unable to walk up a flight of stairs or at least 2 blocks on level ground (i.e., functional capacity \\\u003C 4 METs), or unable to get up from a supine to a standing position without assistance\n* Participation in another interventional study that might interfere with or confound study procedures, or known conflict with multiple upcoming study intervention class dates\n* Inability to understand the informed consent form or fill out questionnaires or complete study interviews\n* Any other serious physical or mental issue that, in the opinion of the investigators, would interfere with study participation (e.g., advanced dementia, uncontrolled substance use or serious mental illness, life expectancy \\\u003C6 months)",{"count":274,"type":21},220,[95],"A randomized, parallel-group, investigator-blinded, comparative effectiveness trial of a fully remote, videoconference-based pelvic floor yoga program versus a physical conditioning program for women with chronic pelvic pain syndrome.",[278,279,28],"Chronic Pelvic Pain Syndrome (CPPS)","Chronic Pelvic Pain Syndrome","2026-03-04",{"date":282,"type":37},"2026-03-06",{"date":284,"type":37},"2025-05-12",{"date":286,"type":21},"2029-03-15",{"name":288,"class":44},"University of California, San Francisco",{"id":290,"slug":4,"hasResults":11,"nctId":12,"briefTitle":291,"officialTitle":292,"acronym":15,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":25,"conditions":296,"keywords":297,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":301,"leadSponsor":302,"locationsCount":45},"100592581","Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea","Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea: a Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n* Adult women who are not menopausal,\n* Experiencing severe dysmenorrhea, defined as an average pain intensity score ≥ 6\u002F10 on a Numerical Rating Scale (NRS) over the past 3 months at the inclusion visit,\n* Having failed optimal first-line medical treatment combining hormonal therapy and appropriate analgesics (Level I and II analgesics, and NSAIDs),\n* Having undergone a pelvic MRI within 6 months prior to the inclusion visit that shows no evidence of deep infiltrating endometriosis or endometrioma, following systematic review by radiologists from the expert center managing the patient (if the pelvic MRI is deemed of insufficient quality for interpretation, a new MRI will be performed at the center),\n* Using a highly effective method of contraception (failure rate \\\u003C1%) for the entire duration of the follow-up period. Highly effective contraception methods are defined as one of the following: combined hormonal contraception (containing estrogen and progestin) with ovulation inhibition (oral, vaginal, or transdermal), progestin-only hormonal contraception with ovulation inhibition (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormonal system (IUS), condoms, bilateral tubal occlusion, vasectomized partner, or sexual abstinence,\n* Having a negative urine pregnancy test on the day of the procedure,\n* Having signed the informed consent form for the study at the M-1 visit.\n\nExclusion Criteria:\n\n* Pregnant or planning a pregnancy during the entire study period,\n* Currently breastfeeding,\n* Refusal to use effective contraception during the study and for 6 months after its completion,\n* Contraindications to botulinum toxin, including:\n* Generalized disorders of muscular activity (e.g., myasthenia gravis, Lambert-Eaton syndrome),\n* Ongoing treatment with aminoglycosides, peripheral muscle relaxants, or amino-4-quinolines,\n* Hypersensitivity to the active substance, human albumin, or sucrose,\n* Bleeding disorders or current treatment with anticoagulants,\n* Ongoing vaginal or upper genital tract infection,\n* Participation in another interventional clinical trial,\n* Inability to cooperate or understand the study requirements in a way that would allow strict adherence to the protocol,\n* Subject to legal protection measures (e.g., guardianship, curatorship, or judicial protection),\n* Not affiliated with the French social security system,\n* Unable to access the internet to complete questionnaires at Month 1 and Month 6.",{"count":20,"type":21},[24],[27,28],[30,31,32],{"date":299,"type":37},"2026-02-12",{"date":39,"type":37},{"date":41,"type":21},{"name":43,"class":44},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":185,"minAge":18,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100611175","evaluation-of-the-analgesic-effect-of-direct-current-stimulation-in-the-treatment-of-pelvic-pain-comparing-three-groups-trans-spinal-stimulation-ganglionic-stimulation-and-placebo-a-randomized-double-blind-study-100611175","NCT07237165","Evaluation of the Analgesic Effect of Direct Current Stimulation in the Treatment of Pelvic Pain, Comparing Three Groups: Trans-spinal Stimulation, Ganglionic Stimulation, and Placebo. A Randomized Double-blind Study","SPINALSTIM","Inclusion Criteria:\n\n* Patient aged 18 to 85 years, suffering from pelvic pain for more than one year (excluding musculoskeletal causes).\n* Patient with stable ongoing medication (analgesic or otherwise) for at least one month.\n* Patient for whom lack of response to conventional treatments has led the pain specialist or referring physician to consider non-pharmacological therapeutic options.\n* Patient reporting a pain intensity score \\>3 on the Numeric Visual Pain Scale (NVPS) during pre-screening.\n* Patient affiliated with the national health insurance system or an equivalent scheme.\n* Patient who has provided written informed consent.\n\nExclusion Criteria:\n\n* History of drug addiction.\n* History of psychiatric disorders likely to interfere with the proper conduct of the study.\n* Patient with skin lesions in the lumbar region.\n* Person unable to understand the study protocol.\n* Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code, corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, or under legal protection.\n* Subject currently in the exclusion period of another clinical trial","85 Years",{"count":312,"type":21},60,[95],"The purpose of this study is to evaluate the analgesic effectiveness of direct current stimulation (tsDCS) in the treatment of pelvic pain by comparing three groups:\n\n* Trans-spinal tsDCS stimulation,\n* Ganglionic tsDCS stimulation,\n* Placebo (sham) tsDCS stimulation.",[28],[250,317,318,319,320],"Non-invasive spinal cord neuromodulation","Trans-spinal direct current stimulation (tsDCS)","Trans-spinal stimulation","Dorsal root ganglion stimulation (DRGS)","2025-11-14",{"date":323,"type":37},"2025-11-19",{"date":325,"type":21},"2025-12-01",{"date":327,"type":21},"2029-11-01",{"name":329,"class":44},"University Hospital, Grenoble",2,{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":84},"100592045","phase-1-psilocybin-for-chronic-pelvic-pain-cpp-in-women-a-pilot-feasibility-study-100592045","NCT06988319","Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","Inclusion Criteria:\n\n* Assigned female at birth, age 18-45 years (pre-menopause)\n* CPP for at least 6 months or longer with central sensitization, diagnosed by a provider who specializes in CPP (e.g. MD, DO, NP)\n* CPP with central sensitization includes endometriosis, adenomyosis, uterine fibroids, pelvic congestion, other pelvic inflammatory diseases, irritable bowel syndrome, inflammatory bladder disorders, myalgias, or any combination of the aforementioned1,3\n* Failing at least 1 treatment for CPP. Failed conventional interventions include pharmacotherapy, non-pharmacotherapy (bladder installations, neuromodulation, trigger point injections, anesthetic blocks, surgery), physical therapy, and\u002For psychotherapy (e.g. Cognitive Behavioral Therapy)\n* Participants will be generally healthy with no exclusionary physical or mental health conditions.\n\nExclusion Criteria:\n\n* Pelvic pain that is not defined as chronic (e.g. acute pelvic or vaginal infections such as sexually transmitted infections, urinary tract infections, pregnancy)\n* Have a history of or a current primary psychotic disorder or bipolar disorder type 1\n* Current use of lithium.\n* Ketamine-assisted therapy within 12 weeks of the baseline visit (V3) or hallucinogen use within 6 months of study enrollment (e.g. psilocybin at a dose of 10 mg or 1 gram mushroom or greater, LSD, MDMA, DMT)\n* Cannabis use (THC, CBD). If willing to taper before the baseline visit (V3) the participant can be included.\n* A positive urine drug test for illicit substance use\n* a score of 5 or greater on the Alcohol Use Disorder Identification Test- Consumption (AUDIT-C) indicating heavy alcohol use\n* Suicidal ideation or serious suicide risk as determined by C-SSRS, if baseline score is 4 or greater.\n* Uncontrolled hypertension, cardiovascular disease, chronic neurologic disorders (e.g. Parkinson's disease, dementia, multiple sclerosis, epilepsy)\n* Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation","45 Years",{"count":339,"type":21},15,[341],"PHASE1","The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).",[28],[345,346,103,347],"psilocybin","women","psilocybin assisted therapy","2025-10-08",{"date":350,"type":37},"2025-10-10",{"date":352,"type":21},"2026-01-01",{"date":354,"type":21},"2026-12-31",{"name":356,"class":44},"Oregon Health and Science University",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":22,"phases":368,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":84},"100582331","phase-4-nsaid-use-for-treating-dysmenorrhea-and-preventing-chronic-pelvic-pain-nsaid-heal-100582331","NCT06861920","NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)","Targeting Interindividual Variability in NSAID Responses to Mitigate Chronic Pelvic Pain Risk in Dysmenorrhea (NSAID HEAL)","NSAIDHEAL","Inclusion Criteria:\n\n* aged 18-35\n* individuals who menstruate, with painful periods\n* regular menstrual cycles (every 22-35 days)\n\nExclusion Criteria:\n\n* presence of active pelvic or abdominal malignancies (primary or metastatic)\n* conditions associated with the absence of regular menses such as polycystic ovarian syndrome, pregnancy, or any current use of continuous hormonal medication or contraceptive\n* unable to read or comprehend the informed consent in English\n* presence of other diagnosed chronic back or pelvic pain conditions (including chronic back pain, fibromyalgia, bladder pain syndrome, irritable bowel syndrome, vulvar pain syndrome, and endometriosis-associated pelvic pain)\n* having another diagnosed\u002Fsymptomatic chronic pain condition besides migraines with an average pain score \\>3\u002F10 in the last month when not consuming pain relievers, or that requires daily treatment with opioids (ex. hydrocodone, oxycodone, codeine, morphine, hydromorphone, tapentadol, tramadol) or neuromodulators (also known sometimes as antidepressants \\[ex. amitriptyline, nortriptyline, imipramine, duloxetine, milnacipran, venlafaxine\\] or antiseizure medications \\[ex. topiramate, gabapentin, pregabalin, carbamazepine, lamotrigine\\])\n* current or past history of stomach ulcers\n* current or past history of gastrointestinal (GI) bleeding\n* diagnosis of peptic ulcer disease\n* current or past history of renal disorders\n* current or past history of adrenal dysfunction\n* diagnosis of liver disorders\n* diagnosis of chronic acid reflex (i.e. GERD)\n* Diagnosis of Crohn's disease or ulcerative colitis\n* Coagulopathy\n* Prolactinoma\n* Von Willebrand disease\n* Platelet disorders\n* High blood pressure that is difficult to manage\n* gastrointestinal conditions or surgeries that affect naproxen absorption\n* bleeding disorders\n* heart failure\n* a history of stroke\n* a history of heart attack\n* active genitourinary or sexually transmitted infection\n* allergy to non-steroidal anti-inflammatory drugs (NSAIDs) or their ingredients\n* individuals who take the following medications: anticoagulants (i.e. warfarin), lithium, diuretics, antacids, angiotensin-converting enzyme (ACE) inhibitors, methotrexate, cholestyramine, or probenecids.\n* Unmanaged diabetes (i.e. Fasting Blood Glucose: ≥ 126 mg\u002FdL (≥ 7.0 mmol\u002FL), Non-Fasting\u002FRandom Blood Glucose: ≥ 200 mg\u002FdL (≥ 11.1 mmol\u002FL), Hemoglobin A1c (HbA1c): ≥ 6.5%)\n* Uncontrolled thyroid function (i.e. Hypothyroidism (Underactive Thyroid): Thyroid-Stimulating Hormone (TSH): \\> 4.5 mIU\u002FL (mild) or \\> 10 mIU\u002FL (severe) Free T4: Below the lower end of the reference range (usually \\\u003C 0.9 ng\u002FdL)\n* Hyperthyroidism (overactive thyroid) (i.e. TSH: \\\u003C 0.4 mIU\u002FL (Suppressed or undetectable), Free T4: Above the upper end of the reference range (usually \\> 2.0 ng\u002FdL)\n* Liver dysfunction (i.e. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or bilirubin (unless known diagnosis of Gilbert's syndrome) ≥ 1.5 times the upper limit of the reference range)\n* Kidney dysfunction (i.e. Serum creatinine \\> 1.1 mg\u002FdL.)","35 Years",{"count":367,"type":21},600,[56],"The goal of this clinical trial is to learn if NSAIDs (i.e. naproxen sodium) can treat menstrual pain and prevent the development of chronic pelvic pain in menstruating adults with painful periods. The main questions it aims to answer are:\n\n* Can non-menstrual pelvic pain reduction be predicted by menstrual pain response to NSAIDs?\n* Will participants with the largest reductions in multi-site sensitivity following NSAID therapy have the largest reductions in non-menstrual pelvic pain?\n\nResearchers will compare naproxen sodium to a placebo (a look-alike substance that contains no drug) to see if naproxen sodium works to treat painful periods.\n\nParticipants will:\n\n* Take naproxen sodium or placebo during several days of their menstrual period every month for 1 year.\n* Complete computer questionnaires and tests from home every 3 months.\n* Complete at-home urine tests to measure hormones every few days for 1-year.\n* Use a pin-prick to collect a small spot of blood, and use a pad or tampon to collect a sample of menstrual blood, and bring it to the research site twice over a 1-year period.\n* Come to the research site twice over a 1-year period to complete sensory assessments and undergo a blood draw.\n\nThe major goal of the study is to develop a multivariable statistical model (see https:\u002F\u002Fgrants.nih.gov\u002Fgrants\u002Fguide\u002Frfa-files\u002FRFA-NS-24-021.html ) describing the factors that effectiveness of pain medication and risk for chronic pain",[371,28,99],"Dysmenorrhea",[373,374,28,99,375],"Painful Periods","NSAIDs","Periods","2025-08-04",{"date":378,"type":37},"2025-08-07",{"date":380,"type":37},"2025-04-07",{"date":382,"type":21},"2030-07",{"name":384,"class":44},"Endeavor Health",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":337,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":395,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":4},"100598963","effect-of-respiratory-exercises-with-pelvic-floor-rehab-on-dyspareunia--autonomic-function-in-women-100598963","NCT07078318","Effect of Respiratory Exercises With Pelvic Floor Rehab on Dyspareunia & Autonomic Function in Women","The Effect of Respiratory Exercises Given in Addition to Pelvic Floor Rehabilitation on Dyspareunia and Autonomic Nervous System in Women With Musculoskeletal Dyspareunia","Dyspareunia","Inclusion Criteria:\n\nFemale participants aged between 18 and 45 years\n\nExperiencing dyspareunia of musculoskeletal origin for at least 6 months\n\nIn a stable sexual relationship and sexually active\n\nWilling and able to attend weekly treatment sessions for 8 weeks\n\nAble to provide informed consent\n\nNo pelvic surgery within the last 6 months\n\nNormal cognitive function and ability to follow instructions\n\nBaseline FSFI score indicating sexual dysfunction (e.g., ≤ 26.55)\n\nExclusion Criteria:\n\n* Presence of neurological, gynecological, or urological pathologies causing pelvic pain (e.g., endometriosis, pelvic inflammatory disease)\n\nPregnancy or postpartum period within the last 6 months\n\nDiagnosed psychiatric disorders (e.g., major depression, psychosis)\n\nUse of medications that affect autonomic nervous system function (e.g., beta-blockers, antidepressants)\n\nHistory of pelvic radiation, cancer, or pelvic trauma\n\nParticipation in other rehabilitation or psychotherapy programs during the study period\n\nInability to tolerate manual therapy or perform breathing exercises\n\nBMI \\> 35, which may interfere with ultrasonographic assessment\n\nNon-compliance risk, such as irregular attendance or language barriers",{"count":394,"type":21},45,[95],"Background and Aim:\n\nDyspareunia, or pain during sexual intercourse, is a common component of female sexual dysfunction and may have multifactorial origins, including musculoskeletal and autonomic factors. While pelvic floor rehabilitation is an established treatment approach for musculoskeletal dyspareunia, it may not sufficiently address the autonomic dysregulation commonly observed in chronic pain conditions. The aim of this study is to investigate the effects of adding diaphragmatic breathing exercises and diaphragm manual therapy to standard pelvic floor rehabilitation on pain severity, pelvic floor function, and autonomic nervous system regulation in women diagnosed with musculoskeletal-origin dyspareunia.\n\nMethods:\n\nThis randomized controlled clinical trial will be conducted between September 1, 2025, and December 1, 2025, at the Kurbaa Training and Consultation Center in Istanbul. A total of 45 participants aged 18-45 years who meet the inclusion criteria will be randomly assigned into three equal groups (n = 15):\n\nGroup I: Pelvic floor rehabilitation only\n\nGroup II: Pelvic floor rehabilitation + diaphragmatic breathing exercises\n\nGroup III: Pelvic floor rehabilitation + diaphragmatic breathing exercises + diaphragm manual therapy\n\nInterventions will be administered once per week for 8 weeks. Pre- and post-intervention assessments will include pain intensity (Visual Analog Scale), pelvic floor muscle function (ultrasonography), sexual function (Female Sexual Function Index), anxiety level (Beck Anxiety Inventory), and autonomic regulation (Heart Rate Variability using Elite HRV). Statistical analyses will be performed using SPSS with significance set at p \\\u003C 0.05.\n\nExpected Contribution:\n\nThis study is expected to contribute to the development of more comprehensive treatment protocols for dyspareunia by integrating physical and neurophysiological rehabilitation components. It may also provide evidence supporting the role of autonomic regulation in improving treatment outcomes for female sexual pain disorders.",[398,399,28],"Dyspareunia (Female Excluding Psychogenic)","Female Sexual Dysfunction (FSD)",[391,401,402,403,404],"Pelvic Floor Rehab","Manual Therapy","Autonomic Regulation","Sexual Dysfunction","2025-07-13",{"date":407,"type":37},"2025-07-22",{"date":409,"type":21},"2025-09-01",{"date":81,"type":21},{"name":412,"class":44},"Sakarya Applied Sciences University",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":84},"100585886","effect-of-radiofrequency-in-women-with-chronic-pelvic-pain-with-an-associated-myofascial-syndrome-versus-myofascial-therapy-and-no-treatment-100585886","NCT06908200","Effect of Radiofrequency in Women With Chronic Pelvic Pain With an Associated Myofascial Syndrome Versus Myofascial Therapy and no Treatment","Effect of Radiofrequency in Women With Chronic Pelvic Pain With an Associated Myofascial Syndrome Versus Myofascial Therapy and no Treatment: a Randomized Clinical Trial","Inclusion criteria included women who were:\n\n* At least 18 years of age\n* Presenting with pelvic pain persisting for at least 6 months\n* Diagnosed with myofascial syndrome of the pelvic floor muscles (PFM) by a specialist based on physical assessment\n* Presenting with pelvic pain intensity greater than 4 on the Visual Analog Scale (VAS) in the last 3 months\n* Agreed to sign the informed consent form.\n\nExclusion criteria included the following:\n\n* Patients who were pregnant\n* Postpartum patients who had given birth within the last year\n* Patients with a history of vulvovaginal pathology\n* Contraindications for the use of radiofrequency: metal implants or active infection\n* Patients with a history of pelvic cancer, including those who had undergone chemotherapy, radiotherapy, and\u002For brachytherapy.",{"count":421,"type":21},80,[95],"A randomised clinical trial is being conducted in the Gynecology Department of the Hospital Clinic de Barcelona in women presenting chronic pelvic pain syndrome due to a myofascial cause which is over a 4 score in the VAS scale and not related to an obstetric injury. This study presents 4 groups; two groups receive 8 radiofrequency sessions, one group receives 8 sessions of myofascial release therapy (MRT) and the last group receives no treatment at all (NT). The two RF groups have been divided into a RF intervention group (RFIG) and a RF control group (RFCG) which receives sham treatment. The RF groups are double-blinded. Other than RF, both groups perform daily Thiele massage at home. The sessions last for 20 minutes and take place once a week during 8 weeks.\n\nThe main variable evaluated is the level of pain during the muscular assessment carried out by an expert pelvic floor physical therapist using the Verbal numeric Scale in the first session and at the end of the 8 sessions. Secondary variables are: sexual function (throughout FSFI questionnaire), pain catastrophizing (ECD), quality of life (EQ5D), anxiety and depression (HADS), central sensitization (CSI) as well as other pelvic floor dysfunction symptoms (PFDI).",[28],[103,426,427,428],"myofascial syndrome","radiofrequency","manual therapy","2025-03-26",{"date":431,"type":37},"2025-04-03",{"date":433,"type":37},"2022-05-10",{"date":435,"type":21},"2025-06-15",{"name":437,"class":44},"Hospital Clinic of Barcelona",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":213,"sex":185,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":217,"phases":4,"briefSummary":448,"conditions":449,"keywords":453,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":4},"100581309","impact-of-equestrian-sports-crossfit-and-gym-training-on-pelvic-floor-health-pelfisport--100581309","NCT06848634","Impact of Equestrian Sports, CrossFit, and Gym Training on Pelvic Floor Health (PELFISPORT )","Impact of Equestrian Sports, CrossFit, and Gym Training on Pelvic Floor Health in Athletes and Non-Athletes: A Cross-Sectional Study","PELFISPORT","Inclusion Criteria:\n\n* Adults 18 years or older.\n* Voluntary participation with signed informed consent.\n* Completion of the online survey.\n* For the sports groups (Equestrian, CrossFit, Gym, Other Sports):\n\n  * Minimum 2 years of experience in the sport.\n  * Minimum 2 training sessions per week.\n\nExclusion Criteria:\n\n* Individuals under 18 years old.\n* Participants who do not complete the survey.\n* Individuals with neurological conditions affecting mobility.\n* Individuals with mobility impairments unrelated to sports.\n* Sports participants with less than 2 years of experience or training less than twice per week.",{"count":447,"type":21},200,"This observational cross-sectional study investigates the impact of equestrian sports, CrossFit, and gym training on pelvic floor health in both athletes and non-athletes. The study aims to determine whether specific sports are associated with a higher risk of pelvic floor dysfunction, including urinary incontinence, pelvic organ prolapse, and chronic pelvic pain.\n\nParticipants will complete an online survey that collects demographic information, sports participation details, and pelvic floor health symptoms. The survey includes standardized questionnaires to assess pelvic floor function. Data will be analyzed to compare the prevalence of pelvic floor issues among different sports and between athletes and non-athletes.\n\nThe study seeks to provide insights into how sports participation influences pelvic health and to raise awareness of pelvic floor dysfunction in both male and female athletes.",[450,451,452,28],"Pelvic Floor Dysfunction","Urinary Incontinence","Pelvic Organ Prolapse (POP)",[454,455,250,456,457,458,459,460],"Urinary incontinence","Pelvic organ prolapse","Equestrian sports","CrossFit","Gym training","Women's health","Physical activity","2025-02-26",{"date":463,"type":37},"2025-02-27",{"date":465,"type":21},"2025-02-28",{"date":467,"type":21},"2025-04-05",{"name":469,"class":44},"University of Oviedo",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":84},"100464175","acupuncture-in-a-multidisciplinary-approach-for-vulvodynia-and-chronic-pelvic-pain-100464175","NCT05324280","Acupuncture in a Multidisciplinary Approach for Vulvodynia and Chronic Pelvic Pain","AMALIA","Inclusion Criteria:\n\n* Women with vulvodynia and\u002For chronic pelvic pain of at least 6 months duration\n* multidisciplinary treatment for at least 3 months\n\nExclusion Criteria:\n\n* Pregnancy\n* Current malignancy\n* Major neurologic or psychiatric morbidity\n* Study participation in Lydia trial (Lasertherapy for vulvodynia)","80 Years",{"count":479,"type":21},68,[95],"Background: Vulvodynia and chronic pelvic pain (CPP) are common and challenging gynecologic pain syndromes. A multidisciplinary approach is recommended.\n\nStudy aim: To study the effectiveness of acupuncture as part of a multimodal treatment for women with vulvodynia and CPP.\n\nDesign: Randomised controlled clinical study\n\nStudy Population: Recruitment from a University outpatient clinic Study groups: Participants will be randomised (1:1)\n\n* Acupuncture group\n* Waiting list control group\n\nSample size: 68 patients\n\nStudy outcome\n\n* Subjective Pain Perception (VAS)\n* Health-related quality of life (questionnaires)",[483,28],"Vulvodynia",[485],"acupuncture","2024-12-09",{"date":488,"type":37},"2024-12-12",{"date":490,"type":37},"2022-06-23",{"date":492,"type":21},"2026-07",{"name":494,"class":44},"Medical University of Graz",{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":502,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":508,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":330},"100569692","conservative-care-for-pelvic-pain-c2p2-in-women-service-members-100569692","NCT06697548","Conservative Care for Pelvic Pain (C2P2) in Women Service Members","Conservative Care for Pelvic Pain (C2P2) in Women Service Members: A Multisite, Multigroup Non-inferiority Randomized Clinical Trial With Development of Clinical Decision Tools","Inclusion Criteria:\n\n1\\. Pain of at least 3 months duration in the abdominal-lumbopelvic area, defined as below the umbilicus, between the two ilia, and above the pubic symphysis including the vulvar, perineal, and vaginal regions.\n\nExclusion Criteria:\n\n1. Sign that pelvic pain may be due to other serious medical issue (recent history of abdominal pelvic surgery, current infection, disrupted tissue integrity, neoplasm, or history of radiation to the pelvic floor tissue or the tissues being measured for stiffness).\n2. Chronic debilitating medical conditions (e.g., fibromyalgia, lupus, complex regional pain syndrome, multiple sclerosis or other progressive neurologic condition).\n3. Currently pregnant or pregnancy in the last 6 months.\n4. Body mass index over 33 (Waco participants only due to limitation of the instrumentation).\n5. Soldiers in an Advanced Individual Training (AIT) status.\n6. Previous intervention to address lumbopelvic muscle stiffness or pain such as dry needling, injections, or soft tissue intervention of any kind in the past 6 months.\n7. Inability to read English at an 8th grade reading level (any participant unable to read the informed consent form, which will be written at an 8th grade level).\n8. Inability to legally provide informed consent for any other reason.","50 Years",{"count":504,"type":21},300,[95],"This study will test the effectiveness of emerging conservative interventions for treatment of chronic pelvic pain (CPP) that can be performed without intravaginal specialization. Participants with CPP will be randomly assigned to one of three groups. The first group will receive treatment based on what they normally would receive, including medications, education, and exercise (Usual Care Group). The second group will receive contemporary non-vaginal treatment including manual therapy, dry needling, and specific breathing training (Emerging Field-expedient Care Group). The third group will receive intravaginal treatment by a pelvic health specialist (Gold-standard Intravaginal Specialist Care Group). Participants will be asked about their pain and symptoms and have measurements taken of their pelvic and back muscles after 1, 3, 6, and 12 months. In addition to seeing which treatments work best, clinical decision tools (using medical and trauma history along with clinical examination) will be developed to identify women with CPP likely to respond favorably to non-vaginal conservative interventions. This study will help determine the best non-vaginal treatment strategies for women with CPP and help clinicians quickly determine which patients are likely to benefit from treatment by non-pelvic health physical therapists (e.g., in theater), vs. patients who should be referred for pelvic health specialty care.",[28],[509,250,510,511,512],"Pelvic health","Physical therapy","Military","womens health","2024-11-19",{"date":515,"type":37},"2024-11-20",{"date":517,"type":21},"2025-01",{"date":519,"type":21},"2028-06",{"name":521,"class":44},"Baylor University",{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":545},"100567816","phase-2-vaginal-photobiomodulation-for-chronic-pelvic-pain-100567816","NCT06673108","Vaginal Photobiomodulation for Chronic Pelvic Pain","Vaginal Photobiomodulation for Chronic Pelvic Pain: a Randomized Controlled Trial","VOICE","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. CPP for 3 months or longer;\n3. Overall pelvic pain severity ≥4 in the last 7 days;\n4. Pelvic muscle tenderness pain level ≥4.\n\nExclusion Criteria:\n\n1. Previous vaginal or vulvar laser therapy;\n2. Receiving concurrent pelvic physical therapy;\n3. Unable to tolerate vaginal\u002Fpelvic examination\n4. Taking drugs that have heat- or light- sensitive contraindications;\n5. Subjectively reports abnormal or decreased sensation in the vagina or rectum;\n6. History of cancer of the cervix, vagina, uterus, bladder, or vulva or suspected of having neoplasia or pre-cancerous lesions;\n7. History of autoimmune inflammatory conditions such as vulvar lichen sclerosis or other types of dermatoses;\n8. History of vaginal trauma, ulcerations, erosions, or other evidence of vaginal and vulvar skin breakdown;\n9. Less than 6 months post-partum;\n10. Actively trying to get pregnant or not willing to use contraception during the trial;\n11. Positive pregnancy test or planning to get pregnant during the study;\n12. Vaginal discharge or bleeding concerning for neoplasia, infectious, or autoimmune condition; \\*\n13. Pelvic pain has not been fully evaluated or pain is not confirmed as chronic pelvic pain;\n14. Does not speak, read, or writes English and thus cannot complete surveys;\n15. Does not have access to smart digital devices or computer, or cannot receive emails.",{"count":531,"type":21},126,[533],"PHASE2","The goal of this clinical study is to determine if 8 treatments with photobiomodulation using near-infrared laser energy can help reduce chronic pelvic pain in women. Additionally, researchers want to determine if treatment with this type of energy can also alleviate pain with activities such as standing, sitting, urinating, having bowel movements and intercourse.",[28,278],"2024-11-01",{"date":538,"type":37},"2024-11-04",{"date":540,"type":37},"2024-10-17",{"date":542,"type":21},"2026-06",{"name":544,"class":176},"SoLa Pelvic Therapy",5,{"id":547,"slug":548,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":502,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":84},"100513846","phase-3-a-study-of-jincaopian-tablets-on-chronic-pelvic-pain-after-pelvic-inflammatory-disease-100513846","NCT05970783","A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease","A Multicenter, Randomized, Double-blind, Dose-parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Jincaopian Tablets in Subjects with Chronic Pelvic Pain After Pelvic Inflammatory Disease","Inclusion Criteria:\n\n* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;\n* The average VAS score of pain in the week before enrollment is ≥4;\n* The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);\n* Women aged 18 to 50 (including 18 and 50) with a history of sexual life;\n* Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pelvic inflammatory disease (acute attack);\n* Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial;\n* Previously diagnosed with cervical intraepithelial neoplasia, primary\u002Fsecondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;\n* Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis;\n* Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;\n* Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;\n* Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;\n* Liver function: ALT or AST\\>1.5 times the upper limit of normal value；Renal function：Scr\\>1.0 times the upper limit of normal value;\n* Serum CA125 and erythrocyte sedimentation \\> 1.1 times the upper limit of normal value.\n* Combined with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases;\n* Have an allergic history to the experimental drug;\n* Have a long history of alcoholism or drug abuse;\n* Intellectual disabilities or mental disorders;\n* Participated in other clinical trials within the past 3 months;\n* The investigator believes that it is not suitable to participate in this clinical trial.",{"count":554,"type":21},414,[24],"The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease",[28],"2024-10-15",{"date":540,"type":37},{"date":561,"type":37},"2022-11-08",{"date":563,"type":21},"2025-04",{"name":565,"class":176},"Beijing Konruns Pharmaceutical Co., Ltd.",{"id":567,"slug":568,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":502,"enrollmentInfo":572,"targetDuration":4,"studyType":217,"phases":4,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":84},"100561023","research-on-the-impact-of-chronic-pelvic-pain-on-endometriosis-100561023","NCT06584760","Research on the Impact of Chronic Pelvic Pain on Endometriosis","Inclusion Criteria:\n\n* 18 to 50 years old;\n* Endometriosis diagnosed through previous surgery (confirmed solely by visual or histopathological examination), endometriosis discovered through imaging examination, deep infiltrating nodules discovered through palpation or imaging examination, and clinically suspected endometriosis;\n* No history of migraine or tension headaches;\n* No history of mental illness (such as restless leg syndrome, chronic fatigue syndrome, fibromyalgia, anxiety or panic attacks, depression).\n\nExclusion Criteria:\n\n* Postmenopausal state (spontaneous or surgical);\n* Previous hysterectomy and\u002For bilateral salpingo oophorectomy (prior to preoperative visit);\n* The patient or authorizer refuses.",{"count":312,"type":21},"Chronic pelvic pain (CPP) is a common disease with multiple systems and multiple causes. In recent years, the incidence rate of CPP in women has gradually increased. It is a pain symptom that originates from pelvic organs or related structures and lasts for more than 6 months. It is closely related to gynecological diseases such as endometriosis (EMs), adenomyosis, pelvic inflammatory disease (PID), uterine leiomyoma, residual ovarian syndrome, pelvic venous congestion syndrome (PCS), etc. But its pathophysiology is very complex and still needs further exploration. Recent studies have shown that central sensitization is an important mechanism for the sustained existence of CPP.\n\nExplore the relationship between chronic pelvic pain and its postoperative outcomes, as well as preoperative endometriosis related questionnaire surveys such as such as Endometriosis Health Profile-30 (EHP-30), Central Sensitivity Inventory (CSI), Simplified McGill Pain Questionnaire (SF-MPQ). Explore the relationship between chronic pelvic pain and its postoperative outcomes, as well as in vitro detection results such as preoperative venous blood, intraoperative pathological tissue immunohistochemistry, ELISA, transcriptome sequencing in patients with endometriosis.",[28,63],[250,63],"2024-09-02",{"date":578,"type":37},"2024-09-05",{"date":580,"type":21},"2024-09",{"date":582,"type":21},"2027-09",{"name":584,"class":44},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":586,"slug":587,"hasResults":11,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":11,"sex":185,"minAge":18,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":217,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":84},"100547846","targeting-the-conus-medullaris-with-ecap-controlled-closed-loop-scs-for-treatment-of-chronic-pelvic-pain-hope-trial-100547846","NCT06413277","Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for Treatment of Chronic Pelvic Pain: HOPE Trial","Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for the Treatment of Chronic Pelvic Pain: HOPE Trial","Inclusion Criteria:\n\n1. Subject is 18 years of age or older at the time of enrollment.\n2. Subject has a minimum Visual Analog Scale (VAS) score of 60 mm or higher (where 100 mm pain) at baseline.\n3. Subject has been diagnosed with chronic intractable pain of the trunk and\u002For limbs specifically related to pelvic\u002Fgenital\u002Fperineal\u002Fanorectal pain, which has been refractory to conservative therapy for a minimum of 6 months.\n4. Subject has pain resulting from a known injury (surgery or trauma).\n5. Subject has been clinically diagnosed with chronic pelvic pain (pain that occurs in the region of the pelvis), including diagnoses such as, but not limited to, complex regional pain syndrome (CRPS types 1 and 2), postsurgical pain, post-traumatic injury pain, interstitial cystitis\u002Fpainful bladder syndrome, post-hysterectomy pain, post-prostatectomy pain, vulvodynia, chronic ovarian pain, and pudendal neuralgia of a known cause.\n6. Subject is an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n7. Subject is willing and capable of giving informed consent.\n8. Subject is willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\n1. Subject is pregnant or nursing.\n2. Subject is involved in a malignancy or injury claim under current litigation or has pending\u002Fapproved worker's compensation claim.\n3. Subject's mechanism of pain is unknown.\n4. Suspected cause and onset of pain are more than 30 days apart.\n5. Subject has history of small fiber neuropathy, mitochondrial disease, fibromyalgia, addiction, CRPS in secondary pain area, and\u002For atypical facial pain.\n6. Subject has been diagnosed with Crohn's Disease, Irritable Bowel Syndrome, ulcerous colitis, or any other inflammatory disease that is ongoing.\n7. Subject has a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator.\n8. Subject has a history of sexual abuse and\u002For sexual trauma.\n9. Subject has a history of unmanaged depression or anxiety that pre-dates the onset of symptoms.\n10. Subject is using greater than 100 MME (morphine milligram equivalents) of opioids at baseline.\n11. Subject shows evidence of an active, disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n12. Subject has previous neuromodulation experience including SCS (Spinal Cord Stimulator) and\u002For DRG (Dorsal Root Ganglion).\n13. Subject has an existing drug pump and\u002For SCS system, or another active implantable device such as a pacemaker, deep brain stimulator, or sacral nerve stimulator.\n14. Subject is concomitantly participating in another clinical study.",{"count":593,"type":21},20,"The aim of the study is to evaluate the effectiveness of using ECAP (electrically evoked compound action potential)-controlled CL (closed-loop) SCS (spinal cord stimulation) to treat chronic pelvic pain by stimulating an area in the spine called the conus medullaris (the lowermost tapering extremity of the spinal cord).",[28,596],"Pudendal Neuralgia",[28,596,598],"Levator Ani Syndrome","2024-05-10",{"date":601,"type":37},"2024-05-14",{"date":603,"type":37},"2024-02-05",{"date":605,"type":21},"2027-01-01",{"name":607,"class":44},"Ainsworth Institute of Pain Management"]